What do you do if you’re head of the ER and one of your physicians is dramatically less efficient than his colleagues, but doesn’t know what he’s doing differently from everyone else?
If Crohn’s disease patients need steroids and immuno-modulators on top of the tumour necrosis factor inhibitor adalimumab, the risk of serious infection is increased, according to a pooled analysis of five clinical trials. The research was presented at the American College of Gastroenterology annual meeting here.
